Targeting Prrx1 can, therefore, be a treatment strategy by reducing CAF plasticity by forcing myCAF differentiation and the conversion of tumor-promoting to tumor-restraining CAFs (Figure 1) [64]. The gene discussed is PRRX1; the disease is neoplasm.